A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1
|
作者：
Gill, Harpaul S. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 13期
关键词：
durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;
D O I：
10.1002/cncr.31996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
引用
收藏
页码：2148 / 2153
页数：6
相关论文
共 50 条
  • [41] Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer
    Rabatic, Bryan M.
    Kong, Feng-Ming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 190 - 194
  • [42] Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
    Wang, Chin-Chou
    Chiu, Li-Chung
    Ju, Jia-Shiuan
    Lin, Yu-Ching
    Fang, Yueh-Fu
    Yang, Cheng-Ta
    Hsu, Ping-Chih
    VACCINES, 2021, 9 (10)
  • [43] The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
    Perdrizet, Kirstin
    Cheema, Parneet K.
    CURRENT ONCOLOGY, 2021, 28 (06) : 5408 - 5421
  • [44] Multimodality Approach to Management of Stage III Non-Small Cell Lung Cancer
    Scarpaci, Anthony
    Mitra, Priya
    Jarrar, Doraid
    Masters, Gregory A.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 22 (02) : 319 - +
  • [45] Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis
    Sugimoto, Takeya
    Fujimoto, Daichi
    Sato, Yuki
    Tamiya, Motohiro
    Yokoi, Takashi
    Taniguchi, Yoshihiko
    Hino, Aoi
    Hata, Akito
    Uchida, Junji
    Fukuda, Yasushi
    Hara, Satoshi
    Kanazu, Masaki
    Matsumoto, Hirotaka
    Kokubo, Masaki
    Yamamoto, Nobuyuki
    LUNG CANCER, 2022, 171 : 3 - 8
  • [46] Stage III Non-small Cell Lung Cancer
    Rusch, Valerie W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 727 - 735
  • [47] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
    Furuhashi, K.
    Hataji, O.
    Nakamura, Y.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Fujiwara, K.
    Nishii, Y.
    Taguchi, O.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
  • [48] Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis
    Zhao, Luqing
    Zhao, Zhiting
    Yan, Xiaoqi
    Wu, Fei
    Sun, Ning
    Guo, Renhong
    Yu, Shaorong
    Hu, Xiao
    Feng, Jifeng
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [49] Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy
    Dang, Jun
    Li, Guang
    Zang, Shuang
    Zhang, Shuo
    Yao, Lei
    RADIATION ONCOLOGY, 2014, 9
  • [50] Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Liang, Huan-Wei
    Liu, Yang
    Pan, Xin-Bin
    AGING-US, 2024, 16 (01): : 857 - 871
12345